FDA Panel Votes Unanimously to Approve GSK Shingles Vaccine

Article

Shingrix represents a new, possibly better alternative to existing treatments.

On Sept. 13, 2017, members of a US FDA advisory panel unanimously voted for approval of GlaxoSmithKline’s (GSK) new shingles vaccine, Shingrex, as a way to prevent shingles in adults age 50 and over.  According to Reuters, reviewers voted 11 – 0 for approval of the vaccine, which Thomson Reuters analysts predict will achieve $1 billion in sales by 2023.

Shingrix contains an immune adjuvant, QS-21 Stimulon, developed by Agenus, that is said to boost efficacy.  Shingles affects mainly older people, and results from reactivation of the varicella-zoster virus, which causes chickenpox and remains latent in those who have had that disease.

In clinical trials, the vaccine remained about 90% effective in patients over age 70, where other vaccines’ efficacy declined over time, Reuters reports.

Panelists questioned the incidence of certain reported adverse health issues among Shingrix recipients, including gout and stroke, according to Reuters, but GSK scientists do not believe that these were related to the compound, and have proposed launching a post-approval safety monitoring plan.

Source: GSK, Reuters

Newsletter

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Recent Videos
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
DC skyline at night with view of the White House and the Washington Monument | Image Credit: © Jessica - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.